Symphogen A/S Names New Chief Scientific/Medical and Business Officers

COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced today the completion of its senior management team with the addition of a new Chief Scientific/Medical Officer, Ivan D. Horak, M.D., FACP and a new Chief Business Officer, Gayle M. Mills.